secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001104659-26-049874
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 7.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead completes $7.8B acquisition of Arcellx; adds anito-cel CAR T therapy for multiple myeloma
--------------------------------------------------------------------------------

- Purchase price $115/share cash plus $5 CVR (contingent on $6B anito-cel sales by end-2029); total implied equity ~$7.8B.
- Tender offer accepted 38.8M shares (~77.2% of outstanding); merger completed April 28, 2026.
- Expected EPS dilution of ~$5.57-$5.67 in 2026; ex-R&D, modestly dilutive 2026-27, accretive from 2028.
- Full control of anito-cel eliminates profit-sharing/royalty obligations; accelerates development and commercial launch.
- Arcellx becomes wholly owned subsidiary of Gilead; ACLX common stock to be delisted from Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465926049874/0001104659-26-049874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465926049874/tm2612748d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-049874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer